Pilot Study Evaluating the Safety and Efficacy of Open-Label Olanzapine
Status:
Terminated
Trial end date:
2006-02-01
Target enrollment:
Participant gender:
Summary
Inpatient Study Evaluating the Safety and Efficacy of Open-Label Olanzapine Monotherapy in
Treatment Refractory Bipolar Mania: This study recruits adult subjects who are diagnosed with
Bipolar I Disorder and presently experiencing an episode of mania. Patients must be willing
to spend initial 7 days in the hospital to observe response to medication. Patients must be
refractory (intolerant or non-responsive) to treatment with lithium and valproate or
carbamazepine. Patients receive study-related care at no cost. This study is sponsored by Eli
Lilly and Company.